Already have an account?

Login with an existing Projects In Knowledge account
New to Projects In Knowledge?

Register today to customize your experience.
Log In
Don't have an account yet? Click here to register

Register for Free
Already have an account? Click here to log in

Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.

Forgot Password

Please Enter your email address.

  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact

Revision date: This policy was last updated on September 30, 2003.

Education Initiative in Oncology

  • Multiple Myeloma — Case Study: Management of Relapsed/Refractory Multiple Myeloma With Anti-CD38 Antibodies – @Point of Care Chapter
  • Multiple myeloma (MM) is the most common and fatal hematologic disorder in adults. Patients inevitably experience relapses and become refractory to therapies. Studies have shown that progression-free survival (PFS) decreases with each new line of therapy, with a 5-year overall survival (OS) rate of less than ... more >>
  • Leukemia — Covid and CLL: Seroconversion Problematic Despite Third SARS-CoV-2 Vaccine Dose – BreakingMED
  • That patients with chronic lymphocytic leukemia (CLL) and other hematologic cancers have lower seroconversion rates after a 2-dose course of SARS-CoV-2 vaccination has been well documented. Now, researchers are finding that these lower seroconversion rates occur even after three doses of the vaccine.
    V. Abramson, MD
  • Cancer Care Considerations — One Target, Many Cancers: Chasing B7-H3 – BreakingMED
  • In STRIVE-02, a first-in-human phase I trial of systemic B7-H3 CAR-T cell therapy in children and young adults with relapsed/refractory solid tumors, the treatment achieved stable disease in three out of nine patients.
    V. Abramson, MD
  • Cancer Care Considerations — ADCs Hold Promise for NSCLC – BreakingMED
  • Moving from concept to clinic is a journey that frequently recalls Sisyphus’ struggle to push a boulder uphill. Yet, in the real world of oncology, cancer researchers doggedly seek a new path to the top—not a shortcut, but a slightly altered route, like the voice of a navigation system noting a delay ahead ... more >>
    V. Abramson, MD
  • Lung Cancer — NSCLC Central Nervous System Mets: Local or Systemic Therapy? – BreakingMED
  • As many as 40% of patients with KRASG12C-mutated non-small cell lung cancer (NSCLC) have brain metastases at the time of diagnosis, and until recent years, the standard approach would be to treat central nervous system (CNS) metastases locally before initiating systemic therapy. However, the availability of ... more >>
    V. Abramson, MD
  • Lung Cancer — NSCLC: Parsing the Checkpoint Inhibitor Benefit – BreakingMED
  • If medical research followed a Hollywood script, non-small cell lung cancer (NSCLC) would be “conquered” following Occam’s razor methodology: identify the simplest of competing theories and forge ahead. But as more and more targets emerge and agents designed to nail those targets move from bench to bedside, ... more >>
    V. Abramson, MD
  • Lung Cancer — Precision Medicine: A New Target in NSCLC? – BreakingMED
  • The novel antibody-drug conjugate (ADC) tusamitamab ravtansine demonstrated durable efficacy in a phase I/II trial of heavily pre-treated patients with non-squamous non-small cell lung cancer (NSQ-NSCLC).
    V. Abramson, MD
  • Lung Cancer — NSCLC Decisions: IO Monotherapy or IO Plus Chemo? – BreakingMED
  • Immunotherapy (IO) has demonstrated significant benefit in non-small cell lung cancer (NSCLC), but still unclear is whether combining it with chemotherapy can extend that benefit or if single-agent IO is the best option—and what factors should play into that decision: PDL-1 score? NSCLC stage? Patient age? To ... more >>
    V. Abramson, MD
  • Lung Cancer — Adagrasib: A Contender for Optimal Second-Line Therapy in Metastatic NSCLC? – BreakingMED
  • In the world of oncology, the search for breakthrough, game-changing therapies is usually a frustrating one, with success often just beyond the grasp of researchers; however, in the words of one oncologist, “conquering KRAS would be game, set, and match.”
    V. Abramson, MD
  • Gastric Cancer — Case Study: Management of a Patient With Stage III Esophageal Adenocarcinoma – @Point of Care Chapter
  • Despite use of multimodality therapy involving chemoradiation and surgery, the prognosis for patients with advanced gastroesophageal cancers remains poor. Recently, data from clinical trials showing improved survival with use of immunotherapy in early lines of therapy have led to the approval of immune ... more >>
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Immuno-Oncology @Point of Care: A Focus on Head and Neck Cancer
  • Primary and adjunctive treatment approaches for patients with head and neck squamous cell carcinoma are complex to navigate, requiring assessment of patient-specific risk factors, knowledge of treatment recommendations, and input from a multispecialty team. Furthermore, these patients typically have poor ... more >>
    R. Ferris, MD, PhD
  • Chronic Lymphocytic Leukemia @Point of Care
  • Recently approved targeted therapies and emerging immunotherapies for chronic lymphocytic leukemia (CLL) are transforming patient outcomes and the standard of care. To achieve the best patient outcomes, clinicians need to implement individualized treatment plans based upon evaluation of patient ... more >>
    S. Gregory, MD
  • Multiple Myeloma @Point of Care
  • This point-of-care eHandbook delivers a thorough yet concise review of multiple myeloma (MM), its diagnosis and prognosis, and the latest evidence-based data on treatment strategies with insights from top clinical specialists on the novel and emerging therapies that are revolutionizing the management of MM. ... more >>
    S. Lonial, MD
  • Advances in Immuno-Oncology
  • Immuno-Oncology @Point of Care, featuring Jeffrey S. Weber, MD, PhD as Editor-in-Chief, is a clinical support platform that provides comprehensive information on immuno-oncology and the role of immune-based medicines in treating cancer, made up of a progressive series of chapters and other learning tools. It ... more >>
    J. Weber, MD, PhD
  • Non-Small Cell Lung Cancer @Point of Care
  • Advances in our understanding of non-small-cell lung cancer (NSCLC) are leading to new strategies for diagnosis, staging, and treatment. This point-of-care clinical resource can help you stay informed about disease pathogenesis, molecular targets, and current and emerging management strategies based on the ... more >>
    M. Socinski, MD
  • Prostate Cancer @Point of Care
  • In this subchapter, treatment of castration-resistant prostate cancer (CRPC) and resistance to the application of androgen deprivation therapy will be discussed. Links to guidelines and clinical studies throughout this chapter will increase the understanding of the approved and emerging agents for CRPC and ... more >>
    E. Crawford, MD
  • Breast Cancer @Point of Care
  • A vast body of knowledge has accumulated over the decades of research that have been conducted on the etiology and pathogenesis of breast cancer. In spite of this, the etiology and underlying causes of breast cancer are not well-understood. This chapter will examine risk factors for breast cancer as well as ... more >>
    F. Esteva, MD, PhD
  • Prostate Cancer — AE Management for Combination PARPi and AR-Targeted Therapies and Considerations for Managing mCRPC in the African-American Community – Webcast
  • Treatment of patients is an art as well as a science. Part of the art is knowing how to discuss treatment options with patients, which includes discussing potential adverse events associated with each treatment option. Another part is making sure to tailor treatment to the individual patient—but not ... more >>
  • Prostate Cancer — Understanding the Mechanism of Action for PARP Inhibitors and Androgen Receptor-Targeted Therapies in mCRPC – Webcast
  • Although targeting the androgen pathway has been a mainstay of prostate cancer treatment for some time, greater understanding of prostate tumor development and progression has led to use of agents targeting other important molecular pathways in this disease. One such pathway involves repair of DNA damage, ... more >>
  • Prostate Cancer — Biomarkers of PARPi Sensitivity and Examining the Data on Combination PARPi and AR-Targeted Therapies in mCRPC – Webcast
  • Although targeting the androgen pathway has been a mainstay of prostate cancer treatment for some time, greater understanding of prostate tumor development and progression has led to use of agents targeting other important molecular pathways in this disease. One such pathway involves repair of DNA damage, ... more >>
  • Renal Cell Carcinoma — First-Line Treatment of RCC – Webcast
  • Renal cell carcinoma (RCC) comprises nearly 4% of all new cancers, and in recent years, incidence of RCC has been rising. Thankfully, in the same time period, 5-year survival rates have also been increasing as new treatment modalities have been approved. In this program, Drs. Robert Motzer and Eric Jonasch ... more >>
  • Renal Cell Carcinoma — Using Adjuvant Therapy for RCC: Who and How – Webcast
  • Renal cell carcinoma (RCC) comprises nearly 4% of all new cancers, and in recent years, incidence of RCC has been rising. Thankfully, in the same time period, 5-year survival rates have also been increasing as new treatment modalities have been approved. In this program, Drs. Robert Motzer and Eric Jonasch ... more >>
  • Gastric Cancer — Oncology Morning Commute: Targeted Therapies for Gastroesophageal and Colorectal Cancers – Podcast
  • HER2 expression in gastric/gastroesophageal junction and colorectal cancer potentially paves the way for the use of targeted therapies for these cancers. Our faculty discuss these important clinical developments.
  • Gastric Cancer — Oncology Morning Commute: The Emerging Role for Antibody-Drug Conjugates in GI Cancers – Podcast
  • In this podcast our faculty discuss gastrointestinal (GI) cancers and antibody-drug conjugates. How are these new therapies changing the landscape of GI cancer care?
  • Lung Cancer — Oncology Morning Commute: ADCs for NSCLC—Ready for Prime Time? – Podcast
  • Our faculty discuss exciting developments in targeted therapies for non-small cell lung cancer, specifically the promise of antibody-drug conjugates as treatment for this disease. But are they ready for prime time?
  • Lung Cancer — Oncology Morning Commute: Targeting HER2, HER3, and TROP2 in NSCLC – Podcast
  • Our faculty continue their discussion on antibody-drug conjugates and look at some of the promising trials in NSCLC for these promising therapies.
  • Renal Cell Carcinoma — RCC Second-Line Treatment and Beyond: Considerations for Sequencing of Therapies – Webcast
  • Metastatic castration-resistant prostate cancer (mCRPC) is a disease state that can be reached from metastatic castration-sensitive or nonmetastatic castration-resistant states. Due to advances in the early therapeutic landscape, patients who develop mCRPC may have seen a greater number of treatments than in ... more >>
  • Ovarian Cancer — Combination First-Line Maintenance Therapy in Ovarian Cancer – Case Study
  • The landscape of first-line maintenance therapy for advanced ovarian cancer has rapidly evolved. Whereas options were previously limited to olaparib for patients with BRCA mutations and bevacizumab for those without, two new poly (ADP-ribose) polymerase (PARP) inhibitor-based regimens have been approved as ... more >>
    L. Randall, MD, MAS
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA
  • Leukemia — Case Study: Initiation of First-Line Treatment in Patient With Symptomatic CLL and del(17p)/TP53 Mutation – Case Study
  • In this master class, Dr. William Wierda discusses a 64-year-old male patient with untreated chronic lymphocytic leukemia who developed leukocytosis, became symptomatic, and needed treatment. The case considers the initial evaluation and diagnosis of this patient, including his immunologic and genetic profile ... more >>
    W. Wierda, MD, PhD
  • Leukemia — Case Study: Achieving Durable Response After Progression on Ibrutinib – Case Study
  • Ibrutinib has improved survival for patients with relapsed, high-risk chronic lymphocytic leukemia, but patients who relapse after ibrutinib pose a challenging clinical scenario. This case study reviews the efficacy and safety data on treatment options to achieve a durable response in a 74-year-old man who ... more >>
    A. Mato, MD, MSCE
    L. Roeker, MD, MSCE
  • Leukemia — Case Study: Optimizing CLL Management: Venetoclax Dosing and TLS Prophylaxis – Case Study
  • Small-molecule inhibitors have improved outcomes for patients with del(17p)-positive chronic lymphocytic leukemia (CLL), a population with a historically poor prognosis, yet they do pose potentially serious risks. This case study reviews the efficacy and safety data of treatment options for a 78-year-old man ... more >>
    B. Cheson, MD, FACP, FAAAS
    M. Yazdy, MD
  • Multiple Myeloma — High-Risk Relapsing MM: Retreatment With Immunomodulatory Therapy – Case Study
  • Determination of the best treatment for a high-risk multiple myeloma patient is based on a complex set of factors, including risk evaluation, patient comorbidities, patient desires, and the need to achieve a satisfactory response as quickly as possible. In this case, Dr. Lentzsch discusses the problems ... more >>
    S. Lentzsch, MD, PhD
  • Multiple Myeloma — Relapsing/Refractory Multiple Myeloma in a High Risk Patient: Efficacy With Monoclonal Antibody Therapy as Part of Triple Therapy – Case Study
  • Choosing the appropriate therapy for transplant-deferred patients with relapsed multiple myeloma (MM) can be challenging; there are now emerging combination treatments available, each with their own efficacy and safety profiles. This case illustrates the real-life case scenario of a patient with relapsed MM ... more >>
    N. Raje, MD
  • Prostate Cancer — Progressive Metastatic Castrate-Resistant Prostate Cancer – Case Study
  • While prostate cancer is often curable with local treatment, many patients will develop recurrence with metastatic castration-resistant prostate cancer (mCRPC). Several targeted treatments are available for mCRPC, and enrollment into clinical trials plays an important role in management of recurrent disease ... more >>
    T. Dorff, MD
  • Prostate Cancer — Newly Diagnosed Metastatic Prostate Cancer Patient – Case Study
  • This activity reviews a real-life case scenario of a patient with newly diagnosed metastatic hormone-sensitive prostate cancer who was found to have bone metastases. The case reviews available treatment options and highlights the importance of choosing a treatment option based on available clinical data and ... more >>
    N. Agarwal, MD
  • Multiple Myeloma — Treatment of a Relapsing High-Risk Multiple Myeloma Patient – Case Study
  • Today there are many options for the treatment of patients with relapsed multiple myeloma, as well as more treatments in development. This case illustrates the real-life scenario of a patient with relapsed multiple myeloma with evolution of his disease at the time of relapse introducing a high-risk ... more >>
    S. Kumar, MD

    We appreciate our customers and hold ourselves to the highest privacy standards.

    Access My Information or Delete My Information